Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Cancer Biology

Background:

• Chronic lymphocytic leukemia (CLL) treatment has advanced with Bruton's tyrosine kinase (BTK) inhibitors and BCL2 antagonists, becoming the standard of care.
• These novel agents have significantly improved patient outcomes, largely replacing traditional chemoimmunotherapy.
• A subset of CLL patients is now emerging who are refractory or intolerant to both BTK inhibitors and BCL2 antagonists, representing a critical unmet medical need.

Purpose of the Study:

• To propose novel therapeutic strategies for chronic lymphocytic leukemia (CLL) patients with double-refractory disease.
• To explore the potential of targeting the tumor microenvironment as a new treatment avenue for refractory CLL.
• To outline a sequential combination therapy approach for double-refractory CLL.

Main Methods:

• Review and synthesis of current therapeutic landscape in CLL.
• Conceptual framework for targeting the tumor microenvironment in CLL.
• Proposal of sequential combination therapy strategies.

Main Results:

• Identification of a patient group with double-refractory CLL (to BTK inhibitors and BCL2 antagonists).
• Proposal that modulating the tumor microenvironment can overcome resistance to current therapies.
• Development of a sequential, tumor microenvironment-directed combination therapy strategy.

Conclusions:

• Targeting the tumor microenvironment presents a promising therapeutic avenue for double-refractory CLL patients.
• Sequential combination therapies directed at the tumor microenvironment warrant clinical investigation.
• Addressing the unmet need in refractory CLL requires innovative treatment strategies beyond current standards of care.